A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies.

Yongheng Liu, Jingyi Wang, Xi Zhao et al.|Journal of Clinical Oncology|2020

Cited by 50